(Q46890990)

26 December 2017

title

Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children (English)

1 reference

26 December 2017

author name string

Inagaki J

1

1 reference

26 December 2017

Nagatoshi Y

2

1 reference

26 December 2017

Hatano M

3

1 reference

26 December 2017

Isomura N

4

1 reference

26 December 2017

Sakiyama M

5

1 reference

26 December 2017

Okamura J

6

1 reference

26 December 2017

language of work or name

English

0 references

publication date

19 November 2007

1 reference

26 December 2017

Bone Marrow Transplantation

published in

1 reference

26 December 2017

volume

41

1 reference

26 December 2017

issue

6

1 reference

26 December 2017

page(s)

571-577

1 reference

26 December 2017

How I treat chronic graft-versus-host disease

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Optimistic expectations and survival after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Molecular and cellular effects of methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Anti-cytokine therapy for the treatment of graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Pathophysiology of graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Pentostatin in steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Chronic graft-versus-host disease: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Rituximab for steroid-refractory chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

Bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

7 January 2021

Chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

7 January 2021

Methotrexate in patients with Crohn's disease after 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

7 January 2021

Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

7 January 2021

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

7 January 2021

Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705922

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705922

1 reference

26 December 2017

1 reference

26 December 2017